###### South Africa
##### Continuum parameters 
        ## Annual rate of: testing, starting ART, stopping ART, viral suppression, loss of suppression 
#### Paper details and citations in One Drive "gmha_master_paper_tracker



#### SABSSM surveys 2002, 2005, 2008, 2012, 2017, 2022 ####

  # Recency of last HIV test, percent tested less than a year ago 

    #2005
      #All respondents 
testing.last.year.15.24.2005 = .494
testing.last.year.25.49.2005 = .366
testing.last.year.50plus.2005 = .325

    #2008
     #By sex
testing.last.year.male.2008 = .515 
testing.last.year.female.2008 = .474

    #2012
      #By sex
testing.last.year.male.2012 = .646
testing.last.year.female.2012 = .675

    #2017
      #By sex
testing.last.year.male.2017 = .662
testing.last.year.female.2017 = .673



#### IeDEA-SA Dashboard ####
  ## Data from IeDEA South Africa clinic and programs 


  # Viral load suppression among patients 12 months after initiating ART, among those who had a viral load test recorded at 12 months after ART initiation
    #2010
vls.male.10.19.2010 = .76
vls.male.20.29.2010 = .81
vls.male.30.39.2010 = .86
vls.male.40.49.2010 = .85
vls.male.50plus.2010 = .87

vls.female.10.19.2010 = .78
vls.female.20.29.2010 = .85
vls.female.30.39.2010 = .88
vls.female.40.49.2010 = .91
vls.female.50plus.2010 = .93

    #2014
vls.male.10.19.2014 = .65   #small sample size n=26
vls.male.20.29.2014 = .88
vls.male.30.39.2014 = .90
vls.male.40.49.2014 = .90
vls.male.50plus.2014 = .91

vls.female.10.19.2014 = .87
vls.female.20.29.2014 = .88
vls.female.30.39.2014 = .88
vls.female.40.49.2014 = .91
vls.female.50plus.2014 = .92

    #2017
vls.male.10.19.2017 = .83
vls.male.20.29.2017 = .88
vls.male.30.39.2017 = .87
vls.male.40.49.2017 = .87
vls.male.50plus.2017 = .91

vls.female.10.19.2017 = .85
vls.female.20.29.2017 = .86
vls.female.30.39.2017 = .92
vls.female.40.49.2017 = .89
vls.female.50plus.2017 = .96


  # ART initiation within 12 months of enrollment in HIV care, in ART-naive patients
    #2010
art.start.male.10.19.2010 = .53
art.start.male.20.29.2010 = .54
art.start.male.30.39.2010 = .76
art.start.male.40.49.2010 = .82
art.start.male.50plus.2010 = .81

art.start.female.10.19.2010 = .29
art.start.female.20.29.2010 = .62
art.start.female.30.39.2010 = .79
art.start.female.40.49.2010 = .79
art.start.female.50plus.2010 = .82

    #2014
art.start.male.10.19.2014 = .52
art.start.male.20.29.2014 = .58
art.start.male.30.39.2014 = .71
art.start.male.40.49.2014 = .78
art.start.male.50plus.2014 = .82

art.start.female.10.19.2014 = .40
art.start.female.20.29.2014 = .65
art.start.female.30.39.2014 = .74
art.start.female.40.49.2014 = .74
art.start.female.50plus.2014 = .75

    #2017
art.start.male.10.19.2017 = .91
art.start.male.20.29.2017 = .85
art.start.male.30.39.2017 = .93
art.start.male.40.49.2017 = .94
art.start.male.50plus.2017 = .95

art.start.female.10.19.2017 = .78
art.start.female.20.29.2017 = .87
art.start.female.30.39.2017 = .91
art.start.female.40.49.2017 = .93
art.start.female.50plus.2017 = .94



